Influenza A virus is a major respiratory pathogen in swine that leads to significant economic loss in the swine industry, and there is a critical need to improve on commercial vaccines. Traditional vaccines target the hemagglutinin (HA) portion of the IAV virus, lose protection to as viruses change, and may even lead to vaccine-associated enhanced respiratory disease (VAERD) after infection with a dissimilar influenza virus. A newer replicon particle (RP) vaccine platform targeting the influenza HA protein offers multiple advantages over traditional vaccines for swine, but have not yet been evaluated for the ability to avoid VAERD or the use of HA along with an additional viral vaccine target, such as neuraminidase (NA). In this work we demonstrated RP HA and NA influenza vaccines stimulate immune responses, protect from disease, and avoid VAERD following infection with a distantly related virus. This demonstrates the potential utility of RP vaccines against influenza and the importance in utilizing the NA in influenza vaccine design. Such improvement of IAV vaccines will reduce influenza disease and economic loss in commercial swine and reduce the risk of influenza transmission to people. These data include individual pig responses used in statistical analyses and figures to support the conclusions of the paper.